Wird geladen...
BCR-ABL1 kinase: hunting an elusive target with new weapons
Tyrosine kinase inhibitors such as imatinib, dasatinib and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. Recent report in Cell (Grebien et al., 2011) paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2011
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228864/ https://ncbi.nlm.nih.gov/pubmed/22118668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chembiol.2011.11.001 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|